ERBB2 and gastric cancer: To date, trastuzumab is the unique target agent approved for first-line treatment of HER2-positive metastatic GC in addition to the doublet chemotherapy backbone, due to the fact that all the other targeted agents failed to improve survival outcomes in this setting [4,5].